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Abstract: Fabry disease (FD) is a rare X-linked recessive genetic disorder caused by a deficient activity
of the lysosomal enzyme alpha-galactosidase A (GLA) and is characterised by intra-lysosomal
accumulation of globotriaosylceramide (Gb3). We performed a meta-analysis of peer-reviewed
publications including high-throughput omics technologies including naïve patients and those
undergoing enzyme replacement therapy (ERT). This study describes FD on a systems level using a
systems biology approach, in which molecular data sourced from multi-omics studies is extracted
from the literature and integrated as a whole in order to reveal the biochemical processes and
molecular pathways potentially affected by the dysregulation of differentially expressed molecules.
In this way new insights are provided that describe the pathophysiology of this rare disease.
Using gene ontology and pathway term clustering, FD displays the involvement of major biological
processes such as the acute inflammatory response, regulation of wound healing, extracellular matrix
(ECM) remodelling, regulation of peptidase activity, and cellular response to reactive oxygen species
(ROS). Differential expression of acute-phase response proteins in the groups of naïve (up-regulation
of ORM1, ORM2, ITIH4, SERPINA3 and FGA) and ERT (down-regulation of FGA, ORM1 and ORM2)
patients could be potential hallmarks for distinction of these two patient groups.
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1. Introduction
Fabry disease (FD) is a rare X-linked recessive genetic disorder caused by a deficient activity of the
lysosomal enzyme alpha-galactosidase A (GLA). It is characterised by intra-lysosomal accumulation
of globotriaosylceramide (Gb3) and other related glycolipids sub-types (e.g., glycosphingolipids) in
many cell types, including blood vessels throughout the body. This buildup initiates a cascade of
events, starting with the disruption of basic metabolic processes at the cellular level and progressing to
inflammatory events and cell death, thereby affecting the system as a whole with an increase of renal,
cardiac, cerebrovascular, and skin complications [1,2].
FD is associated with vascular injury and a high recurrence rate of thrombotic events, caused
by decreased levels of thrombomodulin (TM) and increased levels of plasminogen activator inhibitor
(PAI), both playing a role in the regulation of the endothelium and leukocyte interactions [3].
The impairment of the endothelium-dependent vascular dilation triggered by abnormal levels
of nitric oxide (NO) and aberrant activity of the endothelial nitric oxide synthase (eNOS) are known
factors associated with an increased incidence of stroke amongst Fabry patients [4].
In comparison to other lysosomal storage disorders, FD is one of the more common types and
occurs in approximately 1 in 40,000 male births [2]. When racial origins are taken into account,
the majority of the patients are Caucasians; however, it is also found in African Americans and in
subjects of Asian ancestry [5].
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As occurs in other X-linked inherited disorders, males with deleterious mutations have slight to
no residual alpha-galactosidase A activity. Consequently, these patients experience the full range of
disease symptoms. The disease presentation in female carriers is more variable and depends on the
normal-to-mutant ratio of GLA within the different tissues of the body [5–7].
Historically, the average life span of a male patient with FD was around 41 years, if left
untreated, which can be substantially improved by kidney transplants, dialysis, and, more lately,
enzyme replacement therapy (ERT). Thus, at the time, renal failure, heart failure, and stroke were
the most common causes of death [6,7]. FD management and therapy employs the regular use of
agalsidase-alpha (Replagal) and agalsidase-beta (Fabrazyme). They are reported as improvers of renal
and cardiac function, and cerebrovascular flow [1,8].
The introduction of enzyme replacement therapy for FD posed a major advance in the treatment
of lysosomal storage diseases [9], but monitoring the effects of enzyme replacement therapy in the
clinical practice is challenging as there are no robust surrogate markers of short-term response [10].
Mouse GLA shares a high homology with human GLA; therefore, the GLA-knockout mouse
model of FD has been widely used in studies performing microarray gene expression analysis [11,12].
The FD mouse model presents a normal adult lifespan with normal blood and urine analysis, but has a
number of limitations compared to the human disease including fewer symptoms with no evident
histological lesions in stained sections of the kidneys, liver, heart, spleen, lungs and brain compared
to humans, even though this animal model mimics the main neurological features of FD, including
reduced locomotor activity, impairment of balance and coordination and diminished sensitivity to
painful stimuli. On the other hand, the animal model shows progressive and demarcated accumulation
of Gb3 in the kidneys and liver which makes the mouse model suitable for the development of
enzyme replacement therapies via the assessment of the clearance of accumulated Gb3 in the affected
organs [13].
During the past decade, major advances in the field of omics technologies have led to
an exponential growth in available experimental data. Most of the omics platforms provide
high-throughput, detailed exploration of the genome, transcriptome, proteome and metabolome
through a variety of techniques comprising microarrays for mRNA and miRNA, next-generation
sequencing and mass spectrometry [14].
The intrinsic nature of omics data being noisy and usually on a very large scale causes additional
problems during analysis and concomitantly gives rise to other layers of complexity that are added
due to the biological context, which is often highly diverse [15].
Finding value in complex biological data streams, such as in high-throughput omics platforms,
is the upcoming era for the use of combinatorial integrative approaches using bioinformatics resources
and systems biology methodologies. Thus, the latter approach has the potential to promote an unbiased
and knowledge-driven platform for hypothesis generation in the context of disease modelling. As a
consequence, traditional methods using hypothesis-driven investigations in the study of complex
human disorders are converging to a hypothesis-free systems approach to exploit the potential to yield
an unbiased and novel testable hypothesis as an end-result.
One of the main gaps of the current “panorama” is the disparity between the fast generation of
large-scale data and their in-depth analysis. Hence, a high volume of omics data has been generated
with the goal to discover novel disease biomarkers. Although it found its way into publicly available
databases, no effort has been made to combine and consolidate these resources in order to offer an
integrative view of all studies.
Omics studies and publications concerning Fabry disease are scarce and even more so for the
availability of the underlying raw data. Thus, using the end-results of publications, i.e. tables and lists
containing detected molecules, fold-changes in disease, statistical scores and other relevant molecular
information acquired from omics discovery platforms as data source for a further meta-analysis,
appears to be an alternative to fulfil the absence of native FD datasets.
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Here, we describe FD at a systems level using a systems biology approach, in which molecular
data sourced from multi-omics studies was extracted from the literature and integrated as a whole,
in order to reveal the biochemical processes and molecular pathways potentially affected by the
dysregulation of differentially expressed molecules and in this way provide new insights that describe
the pathophysiology of this rare disease.
2. Materials and Methods
2.1. Data Mining
Several search strings were used in the PubMed literature database in order to cover the topic
of Fabry disease and omics as much as possible using, for example, "Fabry[Mesh] AND (miRNA
OR genomic* OR proteomic* OR metabolomic*) NOT review” (Figure 1A). After the initial search
effort, 76 research papers were retrieved and a preliminary selection criteria was applied taking in
account only papers dealing with human cohorts that made use of a omics biomarker discovery
platform, such as mass spectrometry technologies and microarrays. Publications that focused solely
on characterising one molecule a time were not included. Molecular data concerning differential
expression profiling were gathered from the main body of the literature itself or by using lists and tables
provided in the supplementary material section. Ratios and fold-changes associated with individual
molecules and as well their statistical scores were retained. This resulted in four research publications
characterising molecular differential expression in patients undergoing enzymatic replacement therapy
(ERT) and seven scientific investigations characterising molecular differential expression in FD-naïve
patients (Figure 1A).
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Figure 1. Overview f the analysis workflow used in this st dy from data mining (A) to global
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2.2. Data Biocuration
The step of data curation plays a central role in database development as well as in a systems
analysis, for which the quality of the collected data is verified by comparing it with similar studies and
by assessing the relevance of the parameters used in the detection of a molecule or molecule population,
such as statistical thresholds, normalisation method, applied cut-offs, and validation steps. Reference
databases used for matching an initial cross-platform dataset of 340 redundant molecule entities
were retrieved and mapped to a non-redundant molecular cluster database (CluSO, the clustered
sequences and orthologs database resource from the Pan-omics Analysis Database (PADB) initiative).
This resulted in 192 non-redundant molecule entities (Figure 1B). Additionally, these identifiers enable
a unified and harmonised data-linkage that allows dealing with the high heterogeneity of the data
sourced from multi-omics studies.
Only statistically significant and differently expressed molecules were retained for further
processing (p-value < 0.05, and fold-changes (FC), in which the selected threshold is dependent on
the detection method used by the authors, i.e. transcriptomics FC ≥ 2; proteomics and metabolomics
FC ≥ 1.3).
2.3. Data Pre-Processing
In order to get a focused overview of the associated biological processes and pathways associated
with Fabry disease, molecular information detected in at least two tissues/fluid sources using a
multitude of -omics platforms captured in 11 human studies were taken forward (Table 1, for dataspace
description). This was followed by combining redundant entries within the same study by taking
the mean of the expression ratios of repeated molecules. Then, a global threshold of 1.4 as
fold-change (a 40% increase or decrease of the molecular expression regarding case and control
ratios) and a p-value < 0.05 was applied. Subsequently, a consistency check based on the directionality
(down-regulated if <1.4 and up-regulated if >1.4) of the molecular expression profiles across different
studies was applied in order to remove entries with contradictory regulation and merge consistent
entries by averaging their ratios (Figure 1C).
2.4. Meta-Analysis
We performed functionality tag clustering, statistical gene ontology (GO) and pathway term
clustering, molecular clustering based on protein-protein interactions (PPIs), mapping of the molecular
features into existing pathway maps and the description of putative regulatory interactions (Figure 1D).
Functionalities were obtained from the CluSO database, whereby every single molecular cluster is
assigned a specific deprecated global functionality tag based on a hierarchical system.
GO and pathway term clustering was done using ClueGO v2.2.5 [16] and Cytoscape
(version 3) [17]. GO analysis was done using the GO categories: biological process, molecular function,
cellular component, and pathway descriptors derived from Reactome [18], KEGG (Kyoto Encyclopedia
of Genes and Genomes) [19] and WikiPathways [20]. We applied the two-sided hypergeometric test
as the statistical procedure with Bonferroni step-down correction, kappa score threshold of 0.4 and
p-value enrichment cut-off of 0.05.
Molecular clustering involved the use of GeneMania [21] as a Cytoscape application [17]. Pathway
mapping was achieved using PathVisio (version 3 [22] and a collection of reference pathway maps.
Statistical evaluation included the built-in statistical module using a Z-score cut-off of 1.6449.
We provided the association between gene and disease phenotypes of the most frequently reported
molecules in our dataset for both naïve and ERT groups by using DisGeNET version 2.1 [23], an app
for Cytoscape, which gathers supportive evidence from several public resources and by text-mining
the literature in order to rank gene-disease associations based on our initial queries.
For a view over potential up-stream regulators, we used the CyTargetLinker [24] app for Cytoscape
which displays regulatory elements such as miRNA-target and transcription factor (TF)-target as a
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network based on our initial queries. The CyTargetLinker app uses regulatory information from the
Regulatory Interaction Networks (RegINs).
2.5. Interpretation in the Context of the Disease
The final step in the analysis described here involved the merging of results and the overall
interpretation at a systems level, within which individual results from a multitude of bioinformatics
tools are combined in order to yield biological meaning of the analysis performed (Figure 1E).
3. Results
3.1. Dataspace Description
The datasets extracted from 11 studies sourced from ten research papers and then used in
our meta-analysis are described in Table 1. It handles group modifiers such the description of the
underlying disease and therapies, in addition to cohort number both as a total and split by case and
control scenarios. Moreover, information of the detected molecules in several multi-omics platforms in
two fluid sources are also handled.
Table 1. Description of data sources used in this meta-analysis for both FD-naïve and ERT
groups. EXPREF IDs contain PubMed IDs derived from the publication where data originated from.
N/A: not available.
EXPREF Total N (case) N(control)
Disease
Case Disease Control Source
Detection
Method Reference
Exp25666440 23 11 12 naïve Fabrypatients ERT urine nanoLC-ESI-MS/MS [25]
Exp17301227 13 N/A N/A 6 months ofERT
before treatment
(baseline) blood nanoLC-ESI-MS/MS [26]
Exp18339188a 13 N/A N/A 6 months ofERT
before treatment
(baseline) blood microarray [27]
Exp18339188b 13 N/A N/A naïve Fabrypatients healthy blood microarray [27]
Exp20954982 30 20 10 Fabry healthy urine MALDI-TOF MS [28]
Exp23385635 14 8 6 Fabry healthy blood MALDI-TOF MS [29]
Exp23464927 10 N/A N/A 12 months ofERT
before treatment
(baseline) urine QTOF MS/MS [30]
Exp25619383 46 32 14 Fabry healthy blood LC-MS/MS [31]
Exp21698285 124 35 89 naïve femaleFabry healthy urine CE-MS [32]
Exp26490183 6 N/A N/A short term ofERT
before treatment
(baseline) blood
Illumina MiSeq
instrument [8]
Exp25582508 32 16 16 untreatedFabry males healthy urine UPLC-ESI-TOF-MS [33]
3.2. Functionality Tag Clustering
The naïve group contains globally around five times more overexpressed molecular features
with increased expression levels than decreased, while in the ERT group the number of down-
and up-regulated features is nearly identically distributed (Figure 2). The main functionality tags
accounting for more than 7% and detected in the naïve group were 19%–MET: metabolite; 18%–CS:
Cell shape (cytoskeleton, cell adhesion, morphology, cell junction, cellular structures, extracellular
matrix); 13%–ENZ: enzyme, enzymatic properties; 9%–TP: transport, storage, endocytosis, exocytosis,
vesicles and 9%–SIG: signalling molecules (Figure 2A). In the naïve group, the molecules associated
with the functionality tags of MET: metabolite, TF: transcription and translation, gene regulation,
MOD: modulator, regulator, IGG: Immunoglobulin, and SCA: scaffolder, docking, adaptor, were
found to be exclusively up-regulated, in contrast to the MHC: major histocompatibility complex
and CNL: channel tags that down-regulated (Figure 2B). In the ERT group, 25%–ENZ: enzyme,
enzymatic properties; 25%–CS: Cell shape (cytoskeleton, cell adhesion, morphology, cell junction,
cellular structures, extracellular matrix); 11%–UK: unknown; 9%–IGG: Immunoglobulin; and 8%–TM:
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transmembrane molecules were detected (Figure 2C). In the ERT group, the molecules associated
with the functionalities tags of MOD: modulator, regulator, TF: transcription and translation, gene
regulation, and RCP: receptor were found exclusively to be down-regulated (Figure 2D).
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Figure 2. Functionality tag clustering of the total differentially expressed molecules (N = 151,
fold-change ≥ 1.4 and p-value < 0.05) reported in the literature for the naïve group (A). Associated tags
for deregulated molecules: down (N = 26) and up-regulated (N = 125) molecules (fold-change ≥ 1.4
and p-value < 0.05) reported in the literature for the naïve group (B). Functionality tag clustering of
the total differentially expressed molecules (N = 48, fold-change ≥ 1.4 and p-value < 0.05) reported in
the literature for the ERT group (C). Associated tags for deregulated molecules: down (N = 28) and
up-regulated (N = 20) molecules (fold-change ≥ 1.4 and p-value < 0.05) reported in the literature for
the ERT group (D). MET: metabolite; CS: Cell shape (cytoskeleton, cell adhesion, morphology, cell
junction, cellular structures, extracellular matrix); ENZ: enzyme, enzymatic properties; TP: transport,
storage, endocytosis, exocytosis, vesicles; SIG: signalling; INH: inhibitor (protease, kinase, other
enzymes, pathways); UK: unknown; RCP: receptor; DIS: disease; TF: transcription and translation,
gene regulation; MOD: modulator, regulator; TM: transmembrane; IGG: Immunoglobulin; CHA:
chaperone, chaperonin; SCA: scaffolder, docking, adaptor; MHC: major histocompatibility complex
component/protein cluster (MHC, HLA); CNL: channel.
This primary approach is helpful i t at it provides basic information characterising the functional
rol of the molecul s within the combined datas ts. Therefore, such an approach helps to det rmine
the directionalit of further downstr am an lysis steps, and whether particular areas—e.g., re ulatory
networks (in case of transcriptional factors, miRNAs and their target genes), signalling pathways,
metabolic pathways, and so forth—are more likely to be involved in the disease.
3.3. Expression Correlation Across Fabry Studies and Most Frequent Reported Molecules
Hierarchical clustering was performed using fold-change values of the overlapping features
(16 in total) across all Fabry studies in naïve and ERT patients, and the source fluids (urine and blood)
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which they were detected in as group modifiers (Figure 3). Overall, the expression of the overlapping
molecules across Fabry studies points to an overexpression in the naïve group and a decrease for the
ERT group (Figure 3). It can be observed that the studies Exp25666440 and Exp23464927, from the naïve
and ERT groups, respectively, and both detected in urine, show a molecular expression pattern that is
quite distinct from the other samples/studies. Based on the similarity of the molecular expression,
the detected features can be split into two main clusters: one containing IGK, PTGDS, HBA1, and
AHSG, and another containing UMOD, APOA4, TF, GC, CA1, AFM, GH, RNASE2, PSAP, ORM2,
ORM1, and FGA (Figure 3). A list with the most frequently reported and consistently regulated
molecules in Fabry-naïve and ERT groups can be found in the Supplementary Tables S1 and S2.
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Figure 3. Hierarchical clustering of the differential molecular expression across Fabry studies and by
fluid source. Decreased expression shown in a blue and increased expression by the red colour gradient.
Group modulation for the urine fluid source is shown as light green in a block, whereas for the blood it
is presented as a light green pattern. Group modulation representing the type of treatment is shown as
dark-grey blocks for ERT patients and light-orange blocks for the non-treated patients (naïve group).
3.4. Gene Ontology (GO) Term Clustering
After applying data thresholding (p-value < 0.05 and Fold-change ≥ 1.4) across the entire
dataspace, the Cytoscape plugin ClueGO v.2.2.5 [16] was used to identify the associated biological
processes (BP), molecular functions (MF) and cellular components (CC) using gene ontology (GO)
for both naïve and ERT groups, taking into account overexpressed and under-expressed molecules
(Figures 4 and 5). Pathway term clustering using Reactome, KEGG and WikiPathways can be found in
the Supplementary Figures S1–S5, and Tables S3 and S4, respectively.
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In the GO term analysis of the naïve group, it was found that all the described biological processes
were activated, meaning that the majority of the associated genes with the GO term were overexpressed
(Figure 4A). The process of acute inflammatory response was found to be activated with all the genes
belonging to cluster #1 (Table S3); DEFB1, IL1RN, ITIH4, ORM1, ORM2, SERPINA3, VCAM1 and
VTN increased in expression. In a similar way, the C1QTNF1, COL1A2, COL3A1, FGA, GP6, HSPB1,
RNASE1, and YWHAZ genes associated with platelet activation were also overexpressed,thereby
indicating that the process itself is most likely activated too. The subsequent process of granule
secretion by the platelet (platelet degranulation) involved ALB, APOH, APP, FGA, ITIH4, ORM1,
ORM2, PSAP, SERPINA3, SRGN, and TF genes, and was also found triggered by the overexpression
of the associated genes. Concomitantly, the wound-healing process was found activated with the
genes belonging to cluster #1 (ANXA1, ANXA2, APOH, C1QTNF1, FGA, and VTN) being increased
in expression. The process of regulation of peptidase activity was found activated with the genes
belonging to cluster #1 (APP, CD27, COL28A1, CSTB, ITIH4, NAIP, NGFR, PI3, SERPINA3, SPINK1,
SPINT1, and VTN) being increased in expression. Moreover, by the analysis of the GO molecular
function, this regulation is driven by peptidase inhibitors belonging to the serine type (Figure 4B).
The process of cellular response to reactive oxygen species (ROS) was found activated with the
genes belonging to cluster #1 (ANXA1, APOA4, FBLN5, PRDX1, PSAP, and TXN) being increased
in expression. The process of extracellular matrix organisation (ECM) was found activated with the
genes belonging to cluster #1 (ANXA2, APP, COL11A1, COL1A2, COL3A1, COL4A2, COL4A6, FBLN5,
FBN1, FGA, LTBP2, MATN4, SPINT1, VCAM1, and VTN) being increased in expression. Likewise,
the child GO term of the multicellular organism catabolic process for which the process is driven
by collagen synthesis (collagen catabolic process) involves COL11A1, COL1A2, COL3A1, COL4A2,
COL4A6, and CTSB genes also found to be activated (Figure 4A).
Regarding the GO term associated with the cellular component for the naïve group, it could be
demonstrated that overexpressed genes are located at the extracellular matrix, such as ANXA2, APOH,
COL11A1, COL1A2, COL28A1, COL3A1, COL4A2, COL4A6, DSP, EFEMP2, FBLN5, FBN1, HSP90AA1,
HSPB1, LGALS1, LTBP2, MYL6, PI3, PKM, PRDX1, RNASE1, TGM4, UMOD, and VTN. Located at the
melanosomes with ANXA2, the CTSB, HSP90AA1, PRDX1, RNASE1, and YWHAZ genes increased in
expression. Additionally, basement membrane (basolateral plasma membrane)-associated molecules
ANXA2, COL28A1, COL4A2, COL4A6, EFEMP2, FBN1, and VTN also increased in expression, as did
vacuolar lumen-located molecules APP, CTSB, GC, GLB1, HEXB, HSP90AA1, PSAP (Figure 4C).
A more detailed view of the GO terms associated with the genes/protein for the naïve group can be
found in Supplementary Table S3.
In the GO term analysis of the ERT group, the process of platelet degranulation was found to be
inactivated with the genes belonging to cluster #2 (Table S4); FGA, ORM1, ORM2, PSAP, SERPINF2,
TF decreased in expression. Biological processes such as the acute-phase response and fibrinolysis
were not found to be significantly modulated in between groups, though significantly modulated for
each group, taking into account the cross-correlation of the two initial clusters (cluster #1: up-regulated
genes, and cluster #2: down-regulated genes) since both shared a similar number of up- (~40%) and
down-regulated (~60%) genes (Figure 5A and Supplementary Table S4).
The GO term analysis of the molecular function (MF) revealed the involvement and activation
of scavenger receptor activity (TINAGL1 and LGALS3BP), interleukin-1 receptor activity (IL18R1
and IL1R1), and on the other hand inactivation of isoprenoid binding (PTGDS and RBP4) and
immunoglobulin receptor binding (IGHA2 and IGHG4) (Figure 5B). Regarding the GO term associated
with the cellular component for the ERT group, we found under-expressed genes that are components
of keratin filaments (KRT1, KRT5, KRT6C, and KRT77), secretory granule lumen (FGA, ORM1, ORM2,
SERPINF2, and TF) and components of the cell membrane microparticles circulating in the blood,
blood microparticles (AMBP, FGA, GC, IGHA2, IGHG4, KRT1, ORM1, ORM2, SERPINF2, and TF)
(Figure 5C).
Diseases 2016, 4, 35 9 of 20
Diseases 2016, 4, 35 9 of 20 
 
 
Figure 4. Gene ontology (GO) term clustering (all data) of the naïve group: (A) Biological process (BP), 
(B) Molecular function (MF) and (C) Cellular component (CC). The increase of node size is associated 
with an increase of the statistical significance (Bonferroni-corrected p-value), the red node colour 
denotes an increased regulation of the term/group and green a decrease. Network nodes displayed in 
grey means that they share an equal number of genes/proteins associated with an up- and down-
regulation. 
Figure 4. Gene ontology (GO) term clustering (all data) of the naïve group: (A) Biological process
(BP), (B) Molecular function (MF) and (C) Cellular component (CC). The increase of node size is
associated with an increase of the statistical significance (Bonferroni-corrected p-value), the red node
colour denotes an increased regulation of the term/group and green a decrease. Network nodes
displayed in grey means that they share an equal number of genes/proteins associated with an up-
and down-regulation.
Diseases 2016, 4, 35 10 of 20Diseases 2016, 4, 35 10 of 20 
 
 
Figure 5. Gene ontology (GO) term clustering (all data) of the ERT group: (A) Biological process (BP), 
(B)Molecular function (MF) and (C) Cellular component (CC). The increase of node size is associated 
with an increase of the statistical significance (Bonferroni-corrected p-value), the red node colour 
denotes an increased regulation of the term/group and green a decrease. Network nodes displayed in 
grey means that they share an equal number of genes/proteins associated with an up- and down-
regulation. 
The GO term analysis of the molecular function (MF) revealed the involvement and activation 
of scavenger receptor activity (TINAGL1 and LGALS3BP), interleukin-1 receptor activity (IL18R1 and 
IL1R1), and on the other hand inactivation of isoprenoid binding (PTGDS and RBP4) and 
immunoglobulin receptor binding (IGHA2 and IGHG4) (Figure 5B). Regarding the GO term 
associated with the cellular component for the ERT group, we found under-expressed genes that are 
components of keratin filaments (KRT1, KRT5, KRT6C, and KRT77), secretory granule lumen (FGA, 
ORM1, ORM2, SERPINF2, and TF) and components of the cell membrane microparticles circulating 
in the blood, blood microparticles (AMBP, FGA, GC, IGHA2, IGHG4, KRT1, ORM1, ORM2, 
SERPINF2, and TF) (Figure 5C).  
3.5. Interactome Analysis 
Since not every protein/gene has annotated functions, and in order to cover molecules that are 
either poorly annotated or have no known function, protein-protein interaction clustering was 
performed with both datasets (naïve and ERT groups) representing their respective molecular 
expression using GeneMania app for Cytoscape [17,21] (Figure 6). The displayed networks from the 
Figure 5. Gene ontology (GO) term clustering (all data) of the ERT group: (A) Biological process
(BP), (B)Molecular function (MF) and (C) Cellular component (CC). The increase of node size is
associated with an increase of the statistical significance (Bonferroni-corrected p-value), the red node
colour denotes an increased regulation of the term/group and green a decrease. Network nodes
displayed in grey means that they share an equal number of genes/proteins associated with an up-
and down-regulation.
3.5. Interactome Analysis
Since not every protein/gene has annotated functions, and in order to cover molecules that
are either poorly annotated or have no known function, protein-protein interaction clustering was
performed with both datasets (naïve and ERT groups) representing their respective molecular
expression using GeneMania app for Cytoscape [17,21] (Figure 6). The displayed networks from the
analysis of protein-protein interactions (PPIs) allowed the identification of three highly interconnected
nodes or network hubs in the naïve group: amyloid beta A4 protein (APP), 14-3-3 protein zeta/delta
(YWHAZ), and serum albumin (ALB) (Figure 6A). In the ERT group ALB is one of the enriched
molecules added from the PPI analysis and is shown as a hub of the network cluster. Fibronectin (FN1)
is shown as a cluster hub and is overexpressed (Figure 6B).
Isolated nodes and small clusters (with less than three molecules bonding) were removed in order
to highlight only relevant network features. Globally, the naïve group formed an up-regulated cluster
containing 72 nodes nd 902 edg s. The ERT group formed a down-regulated cluster containing
34 nodes and 429 edges. The most up-regulated molec les for the naïve group clust r ar serglycin
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(SRGN), prostaglandin-H2 D-isomerase (PTGDS), amphiregulin (AREG), tumor necrosis factor receptor
superfamily member 14 (TNFRSF14), desmoplakin (DSP), heat shock protein beta-1 (HSPB1) and
NF-kappa-B inhibitor alpha (NFKBIA). The most down-regulated molecules for the ERT group cluster
are ataxin-7 (ATXN7) and keratin type II cytoskeletal 5 (KRT5). An enriched network with PPIs for
Fabry disease containing additional data from DisGeNET can be found in Supplementary Figure S6.
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3.6. Disease Analysis—DisGeNET
Based on the DisGeNET database score that uses supportive evidence from the literature and
other disease databases to prioritise gene-dise associations, w found GLA, NAT8, NOS3, IL6,
CRP, VDR, NAIP, NOS2, and ICAM1 as the top 10 more accountable associated genes related with
FD (Table S5). Likewise, phe otypes and other traits more similar with FD (based on the number of
shared genes) can be retrieved from DisGeNET. The top 10 disease and phenotype associations for
FD are a multitude of neoplasm and carcinomas from different tissue and/or organ types, such as
malignant neoplasm of breast, breast carcinoma, malignant neoplasm of prostate, liver carcinoma,
Prostate carcinoma, Carcinogenesis, Hypertensive disease, Colorectal Cancer, Neoplasm metastasis,
malignant neoplasm of lung (Table S6). In a similar way one can observe which genes are shared
among Fabry disease with the group of kidney diseases (Table S7).
The naïve group shares more than half of the genes (from an initial gene number of 25)
with malignant neoplasm of breast, breast carcinoma, non-insulin-dependent diabetes mellitus,
and schizophrenia (Table 2). The ERT patients group shares more than half of the genes (from
an initial g ne n mber of 14) with asthma, obesity, Alzheimer's diseas mali nant n oplasm of the
breast (Table 3).
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Table 2. DisGeNET disease analysis for the naïve group.
Disease Name # Shared Genes Gene Name
Malignant neoplasm of breast 16 AGT, ALB, APOA1, APOA4, CLU, GC, GRN, IGK, ITIH4, PSAP, PTGDS,RNASE1, SERPINA3, SLURP1, TF, YWHAZ
Breast carcinoma 15 AGT, ALB, APOA1, APOA4, CLU, GC, GRN, ITIH4, PSAP, PTGDS, RNASE1,SERPINA3, SLURP1, TF, YWHAZ
Diabetes mellitus,
non-insulin-dependent 13
AGT, ALB, APOA1, APOA4, CLU, FGA, GC, GRN, HBA1, PTGDS,
RNASE1, SERPINA3, TF
Schizophrenia 13 APOA1, APOH, CLU, GC, GRN, ITIH4, PSAP, PTGDS, RNASE1, SERPINA3,SHISA5, TF, YWHAZ
Hypertensive disease 12 AGT, ALB, APOA1, CLU, FGA, GC, GRN, PTGDS, RNASE1,SERPINA3, TF, YWHAZ
Liver carcinoma 12 AGT, ALB, APOA1, APOA4, APOH, CLU, FGA, GC, GRN,PTGDS, UMOD, YWHAZ
Diabetes mellitus 12 AGT, ALB, APOA1, APOA4, APOH, CLU, FGA, GC, GRN,PTGDS, UMOD, YWHAZ
Diabetes 12 AGT, ALB, APOA1, APOA4, APOH, CLU, GC, HBA1, PTGDS,SERPINA3, UMOD, YWHAZ
Atherosclerosis 12 AGT, ALB, APOA1, APOA4, APOH, CLU, GC, HBA1, PTGDS,SERPINA3, UMOD, YWHAZ
Arteriosclerosis 12 AGT, ALB, APOA1, APOH, CLU, FGA, GC, HBA1, RNASE1,SERPINA3, UMOD, YWHAZ
Alzheimer‘s disease 12 AGT, ALB, APOA1, APOA4, APOH, CLU, GC, GRN, RNASE1,SERPINA3, TF, YWHAZ
Asthma 11 AGT, APOA1, GC, IGHG1, ORM1, PSAP, PTGDS, RNASE2,SERPINA3, TF, YWHAZ
Obesity 11 AGT, ALB, APOA1, APOA4, APOH, CLU, FGA, HBA1, TF, UMOD, YWHAZ
Cardiovascular Diseases 11 AGT, ALB, APOA1, APOA4, APOH, FGA, HBA1, RNASE1,RNASE2, SERPINA3, TF
Cerebrovascular accident 11 AGT, APOA1, CLU, GC, GRN, PSAP, PTGDS, RNASE1, SERPINA3, TF, YWHAZ
Malignant neoplasm of prostate 11 AGT, ALB, APOA1, APOA4, FGA, GC, GRN, ORM1, PTGDS, TF, YWHAZ
Prostate carcinoma 11 AGT, APOA1, CLU, GC, GRN, PSAP, PTGDS, RNASE1, SERPINA3, TF, YWHAZ
Mammary Neoplasms 10 AGT, ALB, CLU, GRN, HBA1, PSAP, PTGDS, RNASE1, SLURP1, YWHAZ
Colorectal Cancer 10 AGT, ALB, APOA1, CLU, GC, ORM2, PSAP, PTGDS, RNASE1, YWHAZ
Neoplasm metastasis 10 AGT, CLU, GC, GRN, IGK, PSAP, PTGDS, RNASE1, UMOD, YWHAZ
Carcinogenesis 10 AGT, ALB, APOA1, CLU, GRN, PSAP, RNASE1, SERPINA3, TF, YWHAZ
Table 3. DisGeNET disease analysis for the ERT group.
Disease Name # Shared Genes Gene Name
Asthma 8 GC, IGHG1, ORM1, PSAP, PTGDS, RNASE2, SERPING1, TF
Obesity 7 F2, FGA, GC, PTGDS, RBP4, SERPING1, TF
Alzheimer's disease 7 AMBP, F2, GC, IGK, PSAP, PTGDS, TF
Malignant neoplasm of breast 7 F2, FGA, GC, ORM1, PTGDS, RBP4, TF
Atherosclerosis 6 AMBP, F2, FGA, GC, PTGDS, RBP4
Arteriosclerosis 6 AMBP, F2, GC, PSAP, PTGDS, TF
Breast carcinoma 6 F2, FGA, GC, PTGDS, RBP4, TF
Diabetes mellitus,
non-insulin-dependent 5 AMBP, F2, FGA, GC, PTGDS, RBP4
Malignant neoplasm of prostate 5 F2, GC, ORM2, PSAP, PTGDS
Diabetes mllitus 5 AMBP, F2, FGA, GC, TF
Drug-induced liver injury 5 F2, GC, RBP4, SERPING1, TF
Cardiovascular diseases 5 GC, PSAP, PTGDS, RBP4, TF
Liver carcinoma 5 GC, PSAP, PTGDS, RBP4, TF
Colorectal cancer 4 AMBP, F2, FGA, RBP4, TF
Prostate carcinoma 4 AMBP, F2, GC, PTGDS, RBP4
melanoma 4 F2, FGA, GC, TF
Mammary neoplasms 4 F2, FGA, RNASE2, TF
Malignant neoplasm of ovary 4 F2, GC, PSAP, PTGDS
Colorectal carcinoma 4 F2, FGA, GC, RBP4
Diabetes 4 F2, GC, PTGDS, RBP4
Diabetic nephropathy 4 GC, PTGDS, RBP4, TF
3.7. Regulatory Interactions
Network analysis with regulatory interactions was performed using the CyTargetLinker app
for Cytoscape in order to find miRNA-target, transcription factor-target or drug-target interactions
for both dataset groups (naïve and ERT patients) (Figure 7). For this, regulatory data from
designated Regulatory Interaction Networks (RegINs) was used. MicroRNAs (miRNAs) are a class
of endogenous, short ~22 nucleotides in length, which are non-coding RNAs that play an important
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role as post-transcriptional regulators of gene expression. Therefore, molecules affected by the same
up-stream factors are expected to display a similar expression pattern regulation, and consequently
similarly modulated genes might be affected by the same up-stream events.
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Here, it was possible to pinpoint potential up-stream regulators and their targets for the naïve
group (Figure 7A1). Expression of amyloid beta A4 protein (APP) is being regulated by miR-20a,
miR-17, miR-520c-3p, miR-106b and miR-106a. Prosaposin (PSAP) is being regulated by miR-19a,
miR-130b and miR-19b. Extrac llular matrix structural constituents such as the collagen alpha-1(III)
chain (COL3A1) s being regulated by both miR-29b and miR-29c and the co lagen alpha-2(I) chain
(COL1A2) by miR-29c. Ezrin (VIL2) involved in key cytoskeletal structures of the plasma membrane
is being regulated by miR-183. Fibrinogen alpha chain (FGA) is one of the primary components of
Diseases 2016, 4, 35 14 of 20
blood clots and is being regulated by miR-144. Prosaposin (PSAP) and fibrinogen alpha chain (FGA)
are modulators/regulators, respectively, on e.g., lipid binding and e.g., when involved in structural
molecule activity. In our analysis, both proteins were found differentially expressed for the groups of
naïve and ERT patients, up and down-regulated respectively. The PSAP gene expression is regulated
by the following microRNAs and they are expected to be down-regulated: miR-19a, miR-19b and 130b.
FGA gene expression appears to be regulated by miR-144 and by the histone acetyltransferase p300
(EP300) (Figure 7A1,A2,B1). Fibronectin (FN1) binds cell surfaces and various compounds including
collagen, fibrin, heparin, DNA, and actin and is being targeted by miR-200b and miR-200c. Gelsolin
(GSN), a calcium-regulated, actin-modulating protein is being up-stream regulated by miR-124. Erlin-1
(ERLIN1, SPFH1), a lipid-binding protein, is being regulated by miR-34a (Figure 7A2). Similarly,
L-amino-acid oxidase (IL4I1), an enzyme that might play a role in lysosomal antigen processing
and presentation, is being regulated at the transcription level by the following transcription factors:
protein max (MAX), transcription factor COE1 (EBF1), myocyte-specific enhancer factor 2A (MEF2A),
nuclear factor NF-kappa-B p105 subunit (NFKB1), and transcription factor E2F6 (E2F6) (Figure 7B1).
Cadherin-1 (CDH1), a calcium-dependent cell adhesion protein with a strong inhibitory effect on
APP, C99 and C83 production, is being regulated on the transcription level by the hepatocyte nuclear
factor 3-beta (FOXA2). The extracellular sulfatase Sulf-2 (SULF2), an enzyme associated with kidney
development, is being regulated by the double-strand-break repair protein rad21 homolog (RAD21)
(Figure 7B1).
3.8. Merging Results and Overall Interpretation
The combination of all the results from gene ontology, pathway term clustering, interactome
analysis based on PPIs, matching miRNAs to target genes, to linking genes to metabolites through the
analysis of metabolic pathways, leads to the description as a whole based on the several individual
datasets collected for FD. Therefore, clustering based on GO and pathway terms, combined with the
mapped molecules onto pathways, has shown how the regulation of acute-phase response proteins
(FGA, ORM1, ORM2, ITIH4 and SERPINA3) and the platelet degranulation (FGA, TF, ALB, PSAP,
CLU, APOA1) processes were found to be up-regulated, whereas, the regulation (positive) of nitric
oxide biosynthesis process (CLU and AGT) and the regulation (positive) of cholesterol esterification
(APOA1 and AGT) were both found to be down-regulated (Figure 8).
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4. Discussion
In this integrative systems biology meta-analysis, after performing gene ontology and pathway
term clustering, it was found in the Fabry-naïve (non-treated) group that this involves major biological
processes such as the acute inflammatory response, regulation of wound healing, extracellular matrix
(ECM) remodelling, regulation of peptidase activity and cellular response to reactive oxygen species
(ROS). The acute inflammatory response was found activated with all the genes belonging to cluster #1
(DEFB1, IL1RN, ITIH4, ORM1, ORM2, SERPINA3, VCAM1 and VTN) increased in expression.
Platelets are highly specialised inflammatory effector cells for hemostasis and are the first
responders in case of vascular injury and endothelial disruption. They are involved in a full spectrum
of processes from acute inflammation to adaptive immunity, and are actively associated with tissue
remodelling [35–38].
From this analysis, we describe the process of platelet activation (C1QTNF1, COL1A2, COL3A1,
FGA, GP6, HSPB1, RNASE1, YWHAZ) initiated by binding of collagen (COL1A2, and COL3A1) to the
platelet glycoprotein VI (GP6) which in turn leads to signal transduction through the involvement of
FcR gamma-chain, the Src kinases (e.g., Fyn/Lyn) and the linker for activation of T-cell family member 1
(LAT) adapter protein, and therefore leads to the activation of phospholipase C gamma 2 (PLCG2) [39].
Ultimately, the process leads to the activation of the ligand-binding function of integrin beta-3 to bind
fibrinogen alpha chain (FGA). Subsequently platelet adhesion and aggregation is mediated, resulting
in overall platelet spreading, granule secretion (degranulation), stabilisation of platelet adhesion and
aggregation, and finally clot retraction.
The sub-process of granule secretion by platelets (platelet degranulation) from the GO term
association analysis involves ALB, APOH, APP, FGA, ITIH4, ORM1, ORM2, PSAP, SERPINA3, SRGN,
and TF and leads to exocytosis of secretory granules containing preformed mediators such as histamine
and serotonin and in this way amplifies thrombus formation at sites of vascular injury by enhancing
cell activation, reinforcing cell adhesion and inducing cell migration and tissue regeneration and
repair. Platelet granule secretion has an important role in the pathogenesis of ischemic cardio- and
cerebrovascular diseases [40,41]. Additionally, the release of prostaglandin (PTGDS catalyses the
conversion of PGH2 to PGD2) mediators of the inflammation process can contribute to its resolution
and promote wound healing (ANXA1, and ANXA2). Prostaglandin D2 (PGD2) is a prostaglandin
involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation [42].
The wound-healing process was found activated with genes belonging to t cluster #1 (ANXA1,
ANXA2, APOH, C1QTNF1, FGA, and VTN) being increased in expression. Regulation of wound
healing modulates the rate, frequency, or extent of the series of events that restore integrity to a
damaged tissue, following an injury. Annexin A1 (ANXA1) plays an important role in the innate
immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory
process [43].
The process of extracellular matrix organisation (ECM) was found activated with the genes
belonging to cluster #1 (ANXA2, APP, COL11A1, COL1A2, COL3A1, COL4A2, COL4A6, FBLN5,
FBN1, FGA, LTBP2, MATN4, SPINT1, VCAM1, and VTN) being increased in expression. This process
is of main importance for events occurring at early development and for maintenance of tissue
homeostasis; its dysregulation thus leads to aberrant extracellular matrix (ECM) remodelling and
ultimately to the establishment of a disease state. The disruption of the trade-off between production
and degradation of ECM during a chronic tissue injury can lead to the deposition of ECM and then lead
to pathological fibrosis [44]. Fibrosis can be the end-result of tissue injury, inflammation and apoptosis
and is normally considered a final irreversible event. Nevertheless, in some clinical conditions, fibrosis
is an early event and there is evidence that diabetic nephropathy (DN) and Fabry disease (FD) may be
part of such conditions [45,46]. The vascular cell adhesion protein 1 (VCAM1) seems to have a function
in leukocyte-endothelial cell adhesion. It interacts with integrins on leukocytes, and mediates adhesion
and signal transduction. Their interaction with integrins could have a role in the pathophysiology of
the immune response and in leukocyte chemotaxis to sites of inflammation [47].
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The process of regulation of peptidase activity was found activated with the genes belonging
to cluster #1 (APP, CD27, COL28A1, CSTB, ITIH4, NAIP, NGFR, PI3, SERPINA3, SPINK1, SPINT1,
and VTN) being increased in expression. Enzymes with proteolytic activity can exert directly their
action by degrading ECM or indirectly by activating other proteases, which in turn can then degrade
ECM. This process is regulated by a complex array of activators, inhibitors and cellular receptors.
Here, we describe a proteolytic-antiproteolytic imbalance due to an increase of the collagen catabolic
process. This is verified by the increase in expression of collagens (COL11A1, COL1A2, COL3A1,
COL4A2, and COL4A6) and cathepsins (CTSB); the latter is involved in an intricate activation cascade
of proteases that leads to proteolysis, contrasting with the presence of overexpressed protease inhibitors
(PI3, SERPINA3, SPINK1, SPINT1, ITIH4, and CSTB).
The process of cellular response to reactive oxygen species (ROS) was found activated with the
genes belonging to cluster #1 (ANXA1, APOA4, FBLN5, PRDX1, PSAP, and TXN) being increased
in expression. Free radicals react with main cellular components like proteins and lipids and in this
way they are able to modify the balance of the proteolytic-antiproteolytic state,thereby damaging the
cellular membrane. Globotriaosylceramide (Gb3) induces oxidative stress and increases cell adhesion
molecule expression in Fabry disease (FD) endothelial cells [48].
Several studies have implicated miRNAs as potent regulators of the ECM. The miR-29 family,
in our study miR-29b and miR-29c, regulates the expression of COL1A2 and COL3A genes involved in
ECM remodelling. Other mechanisms that limit fibrosis are signalling mediators such as interferon-γ
(IFNγ) and peroxisome proliferator activated receptor-γ (PPARγ) that exert their anti-fibrotic effects
by antagonizing TGFβ signalling. Vitamin D receptor (VDR) ligands can decrease liver fibrosis by
redirecting VDR to SMAD3 sites on the DNA, thereby reducing SMAD3 occupancy. This molecular
competition for binding sites inhibits SMAD3-mediated transcription of ECM targets and prevents
hepatic stellate cell activation in the liver [49]. The association between ECM component dysregulation
and overall disease severity suggests that ECM turnover may play a role in FD pathogenesis [49,50].
Contrasting regulation of acute-phase response proteins and increased platelet degranulation
of the groups of naïve (up-regulation of ORM1, ORM2, ITIH4, SERPINA3, FGA and PSAP) and ERT
(down-regulation of FGA, PSAP, ORM1 and ORM2) patients (Figures 3 and 6) as potential hallmarks
for the distinction between naïve patients and those undergoing ERT. Moreover, proteins secreted
by activated platelets can adhere to the vessel wall and promote the development of atherosclerosis
and thrombosis [51]. The formation of the fibrin clot (blood coagulation cascade) pathway found in
ERT patient groups can make sense, since the core source of patient injury has been attenuated with
treatment by enzymatic therapy.
On the other hand, Vedder and collaborators [52] found that only minimal abnormalities in
markers for platelet, endothelial activation, and coagulation activation and fibrinolysis could be
established in a large cohort of Fabry disease patients. Therefore, they claimed that these abnormalities
are more likely related to renal insufficiency than Fabry disease itself.
Systems biology requires comprehensive data at all molecular levels, hence using a data-driven
approach based in molecular expression profiling of a disease and/or disease states could be a
promising approach to finding potential body fluid disease biomarkers and consequently provide
putative therapeutic targets. Nevertheless, mining the increasing data across different labs is still a
great challenge which affects the efficiency of selecting useful molecular candidates, resulting in the
cumulative increase of redundant and falsely identified molecules. Furthermore, these molecules will
ultimately populate the increasing medical literature and will become a source for biased information
and thus a burden for decision making with respect to candidate disease biomarkers.
5. Conclusions
From our meta-analysis we found evidence to support the hypothesis that an increased endothelial
inflammatory profile exists in Fabry disease, with increased impediment of progressing through the
several phases of wound healing, thus installing a prolonged inflammatory phase. In this way,
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increased levels of protease inhibitors, enhanced phenomena of ECM remodelling, and damage of
survival and growth factors needed to achieve a complete healing are promoted. Concomitantly,
reactive oxygen species (ROS) can chemically modify these vital components.
The pathogenicity of Fabry disease (FD) has been commonly attributed to the long-term and
progressive deposition of globotriaosylceramide (Gb3) in the vascular endothelium; however, this
initial metabolic defect triggers a cascade of molecular events that leads to endothelial dysfunction and,
with the progression of the disease, may promote recurrent thrombotic events during the patient’s life.
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